NuCana (NCNA) Competitors $0.05 +0.00 (+1.92%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.05 0.00 (-0.84%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NCNA vs. EVFM, NMTR, TRVN, PTPI, SYRS, SRNE, BIOR, HEPA, BPTSY, and VRPXShould you be buying NuCana stock or one of its competitors? The main competitors of NuCana include Evofem Biosciences (EVFM), 9 Meters Biopharma (NMTR), Trevena (TRVN), Petros Pharmaceuticals (PTPI), Syros Pharmaceuticals (SYRS), Sorrento Therapeutics (SRNE), Biora Therapeutics (BIOR), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. NuCana vs. Its Competitors Evofem Biosciences 9 Meters Biopharma Trevena Petros Pharmaceuticals Syros Pharmaceuticals Sorrento Therapeutics Biora Therapeutics Hepion Pharmaceuticals Biophytis Virpax Pharmaceuticals NuCana (NASDAQ:NCNA) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability. Does the media refer more to NCNA or EVFM? In the previous week, NuCana and NuCana both had 1 articles in the media. NuCana's average media sentiment score of -0.21 beat Evofem Biosciences' score of -0.99 indicating that NuCana is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NuCana 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evofem Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Which has more risk and volatility, NCNA or EVFM? NuCana has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Which has stronger valuation & earnings, NCNA or EVFM? Evofem Biosciences has higher revenue and earnings than NuCana. Evofem Biosciences is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuCanaN/AN/A-$24.28M-$7.02-0.01Evofem Biosciences$11.39M0.09$52.98M-$0.05-0.18 Is NCNA or EVFM more profitable? NuCana has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. Evofem Biosciences' return on equity of -91.97% beat NuCana's return on equity.Company Net Margins Return on Equity Return on Assets NuCanaN/A -319.85% -88.55% Evofem Biosciences -46.42%-91.97%-61.93% Do analysts prefer NCNA or EVFM? NuCana presently has a consensus price target of $25.00, suggesting a potential upside of 52,310.90%. Given NuCana's stronger consensus rating and higher probable upside, equities analysts plainly believe NuCana is more favorable than Evofem Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders hold more shares of NCNA or EVFM? 44.0% of NuCana shares are owned by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 0.2% of Evofem Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryNuCana beats Evofem Biosciences on 9 of the 14 factors compared between the two stocks. Get NuCana News Delivered to You Automatically Sign up to receive the latest news and ratings for NCNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCNA vs. The Competition Export to ExcelMetricNuCanaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$280K$2.93B$5.56B$9.40BDividend YieldN/A2.44%3.75%4.03%P/E Ratio-0.0119.8828.2219.78Price / SalesN/A305.42435.9298.62Price / CashN/A42.5936.1658.27Price / Book0.047.678.115.65Net Income-$24.28M-$55.28M$3.25B$257.97M7 Day PerformanceN/A4.87%1.61%3.73%1 Month PerformanceN/A11.73%7.26%11.50%1 Year PerformanceN/A3.72%33.13%19.19% NuCana Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCNANuCana3.0625 of 5 stars$0.05+1.9%$25.00+52,310.9%-98.4%$280KN/A-0.0130Positive NewsStock SplitEVFMEvofem Biosciences1.1696 of 5 stars$0.01-1.1%N/A-11.0%$1.09M$11.39M-0.01120Gap UpNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220TRVNTrevena1.2382 of 5 stars$0.91-2.4%$5.00+448.0%-85.2%$875K$443K-0.0240Positive NewsGap DownHigh Trading VolumePTPIPetros PharmaceuticalsN/A$0.03-3.5%N/A-99.7%$857K$5.11M-0.0120Gap DownSYRSSyros Pharmaceuticals4.1374 of 5 stars$0.03+197.0%$3.33+11,011.1%-99.8%$805K$386K-0.01120SRNESorrento Therapeutics0.583 of 5 stars$0.00-45.8%N/A-84.4%$717K$60.32M0.00800High Trading VolumeBIORBiora Therapeutics1.8478 of 5 stars$0.15+6.5%$23.00+15,664.2%-97.9%$660K$892K-0.01120Gap UpHEPAHepion Pharmaceuticals0.168 of 5 stars$0.06-6.2%N/A-99.9%$615KN/A-0.0120BPTSYBiophytisN/A$1.33-8.3%N/A-71.3%$467KN/A0.0030Gap DownVRPXVirpax PharmaceuticalsN/A$0.37+4.7%$75.00+20,164.8%-98.8%$460KN/A0.007 Related Companies and Tools Related Companies Evofem Biosciences Competitors 9 Meters Biopharma Competitors Trevena Competitors Petros Pharmaceuticals Competitors Syros Pharmaceuticals Competitors Sorrento Therapeutics Competitors Biora Therapeutics Competitors Hepion Pharmaceuticals Competitors Biophytis Competitors Virpax Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NCNA) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NCNA Stock Alerts